CFO transition
Rani Therapeutics Holdings, Inc. CFO transition: Nicholas M. Maestas to succeed Svai Sanford
Rani Therapeutics Holdings, Inc. reported in a Form 8-K filed June 30, 2026 that Nicholas M. Maestas will succeed Svai Sanford as Chief Financial Officer (principal financial officer and principal accounting officer), effective June 29, 2026.
In the filing's words
On June 29, 2026, Rani Therapeutics Holdings, Inc. (the “Company”) announced the appointment of Nicholas M. Maestas as the Company’s Chief Financial Officer (principal financial officer and principal accounting officer) effective as of June 29, 2026.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Rani Therapeutics Holdings, Inc. (RANI) |
|---|---|
| Event | Transition |
| Incoming | Nicholas M. Maestas |
| Outgoing | Svai Sanford |
| Title in the filing | Chief Financial Officer (principal financial officer and principal accounting officer) |
| Effective | June 29, 2026 |
| 8-K filed | June 30, 2026 |
| Internal promotion | No |
| Prior role (per filing) | Chief Financial Officer and Head of Corporate Strategy, Tempest Therapeutics, Inc. |
| SEC CIK | 0001856725 |
Rani Therapeutics Holdings, Inc. reported this change in a Form 8-K, Item 5.02, filed June 30, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Nicholas M. Maestas? Send a correction with the primary source.